Free Trial
NASDAQ:ALGS

Aligos Therapeutics (ALGS) Stock Price, News & Analysis

Aligos Therapeutics logo
$7.95 +0.64 (+8.76%)
Closing price 07/3/2025 02:52 PM Eastern
Extended Trading
$7.76 -0.19 (-2.39%)
As of 07/3/2025 04:03 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Aligos Therapeutics Stock (NASDAQ:ALGS)

Key Stats

Today's Range
$7.25
$8.06
50-Day Range
$4.36
$8.37
52-Week Range
$3.76
$46.80
Volume
96,005 shs
Average Volume
211,126 shs
Market Capitalization
$48.57 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$70.00
Consensus Rating
Buy

Company Overview

Aligos Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
76th Percentile Overall Score

ALGS MarketRank™: 

Aligos Therapeutics scored higher than 76% of companies evaluated by MarketBeat, and ranked 243rd out of 929 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Aligos Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Aligos Therapeutics has received no research coverage in the past 90 days.

  • Read more about Aligos Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Aligos Therapeutics are expected to decrease in the coming year, from ($10.36) to ($11.92) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Aligos Therapeutics is -0.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Aligos Therapeutics is -0.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Read more about Aligos Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    12.85% of the float of Aligos Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Aligos Therapeutics has a short interest ratio ("days to cover") of 3.4, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Aligos Therapeutics has recently decreased by 1.94%, indicating that investor sentiment is improving.
  • Dividend Yield

    Aligos Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Aligos Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    12.85% of the float of Aligos Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Aligos Therapeutics has a short interest ratio ("days to cover") of 3.4, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Aligos Therapeutics has recently decreased by 1.94%, indicating that investor sentiment is improving.
  • Search Interest

    Only 1 people have searched for ALGS on MarketBeat in the last 30 days. This is a decrease of -83% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Aligos Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 4.80% of the stock of Aligos Therapeutics is held by insiders.

  • Percentage Held by Institutions

    60.43% of the stock of Aligos Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Aligos Therapeutics' insider trading history.
Receive ALGS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aligos Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ALGS Stock News Headlines

$100 Trillion “AI Metal” Found in American Ghost Town
Jeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could be the biggest technology story of this decade. In short, he believes what he's holding in his hand is the key to the $100 trillion AI boom… And only one company here in the U.S. can mine this obscure metal.
Aligos Stock Price History
See More Headlines

ALGS Stock Analysis - Frequently Asked Questions

Aligos Therapeutics' stock was trading at $39.84 at the beginning of 2025. Since then, ALGS shares have decreased by 80.0% and is now trading at $7.95.

Aligos Therapeutics, Inc. (NASDAQ:ALGS) posted its quarterly earnings results on Tuesday, May, 6th. The company reported ($2.11) earnings per share for the quarter, beating the consensus estimate of ($2.80) by $0.69. The firm earned $0.31 million during the quarter, compared to the consensus estimate of $0.33 million. Aligos Therapeutics had a negative net margin of 1,628.75% and a positive trailing twelve-month return on equity of 14.67%.

Aligos Therapeutics's stock reverse split before market open on Monday, August 19th 2024.The 1-25 reverse split was announced on Thursday, August 15th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Friday, August 16th 2024. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

Aligos Therapeutics (ALGS) raised $150 million in an IPO on Friday, October 16th 2020. The company issued 10,000,000 shares at a price of $14.00-$16.00 per share. J.P.Morgan, Jefferies and Piper Sandler acted as the underwriters for the IPO and Cantor was co-manager.

Shares of ALGS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Aligos Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Athenex (ATNX), Tesla (TSLA), Taiwan Semiconductor Manufacturing (TSM) and Adverum Biotechnologies (ADVM).

Company Calendar

Last Earnings
5/06/2025
Today
7/04/2025
Next Earnings (Estimated)
8/05/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ALGS
Fax
N/A
Employees
90
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$70.00
High Stock Price Target
$70.00
Low Stock Price Target
$70.00
Potential Upside/Downside
+780.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$131.21 million
Net Margins
-1,628.75%
Pretax Margin
-1,618.04%

Debt

Sales & Book Value

Annual Sales
$3.94 million
Price / Cash Flow
N/A
Book Value
($7.50) per share
Price / Book
-1.06

Miscellaneous

Free Float
5,821,000
Market Cap
$48.57 million
Optionable
No Data
Beta
2.77
20 Stocks to Sell Now Cover

Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.

Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.

Get This Free Report

This page (NASDAQ:ALGS) was last updated on 7/5/2025 by MarketBeat.com Staff
From Our Partners